Simon d’Oelsnitz

Mar 6, 2024 | nature.com | Simon d’Oelsnitz |Daniel Diaz |Daniel Díaz |Daniel Acosta |James M. Loy |Hal S Alper | +1 more

AbstractA major challenge to achieving industry-scale biomanufacturing of therapeutic alkaloids is the slow process of biocatalyst engineering. Amaryllidaceae alkaloids, such as the Alzheimer’s medication galantamine, are complex plant secondary metabolites with recognized therapeutic value. Due to their difficult synthesis they are regularly sourced by extraction and purification from the low-yielding daffodil Narcissus pseudonarcissus.

Feb 8, 2024 | nature.com | Simon d’Oelsnitz

AbstractBioengineers increasingly rely on ligand-inducible transcription regulators for chemical-responsive control of gene expression, yet the number of regulators available is limited. Novel regulators can be mined from genomes, but an inadequate understanding of their DNA specificity complicates genetic design. Here we present Snowprint, a simple yet powerful bioinformatic tool for predicting regulator:operator interactions.